Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

NCT03117036 | Recruiting

• 1 other identifier: 2016-11-040
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Conditions

Lymphoma, Non-Hodgkin; Lymphoma, Hodgkin

Keywords

lymphoma; cohort; serum; cell-free DNA

Outcome Measures

Primary Outcomes (1)

• Response rate

  response to chemotherapy

  3 months after chemotherapy

Secondary Outcomes (3)

• Progression-free survival

  3 year

• Overall survival

  3 year

• Biomarker

  3 year

Study Arms (1)

Lymphoma

Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.

Drug: Chemotherapy

Interventions

Chemotherapy DRUG

Systemic chemotherapy with curative intent

Also known as: Treatment

Lymphoma

Eligibility Criteria

• Age: 20 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled

You may qualify if:

• Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
• years
• Patients requiring systemic chemotherapy with curative intent
• Written informed consent

You may not qualify if:

• Myeloid malignancy
• Multiple myeloma
• Patients do not require systemic chemotherapy with curative intent

Sponsors & Collaborators

• Samsung Medical Center: lead
• Samsung Genomic Institute: collaborator

Study Sites (1)

Samsung Medical Center

Seoul, 135-710, South Korea

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

serum and cell-free DNA from patients' peripheral blood

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin; Hodgkin Disease; Lymphoma

Interventions

Drug Therapy; Therapeutics

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Seok Jin Kim, MD, PhD

  Samsung Medical Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Seok Jin Kim, MD, PhD

CONTACT

+82234101766; kstwoh@skku.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 12, 2017
• First Posted: April 17, 2017
• Study Start: March 1, 2017
• Primary Completion (Estimated): December 28, 2026
• Study Completion (Estimated): December 28, 2026
• Last Updated: May 21, 2025

Record last verified: 2025-05

Locations

KR (1)